During the past decade, Carient Heart and Vascular conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 3 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 3 clinical trials were completed. i.e. 75% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Carient Heart and Vascular" #1 sponsor was "Amgen" with 2 trials, followed by "Boehringer Ingelheim" with 2 trials sponsored, "Bayer" with 1 trials sponsored, "Boston Scientific Corporation" with 1 trials sponsored and "Brigham and Women's Hospital" with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Carient Heart and Vascular" #1 collaborator was "Eli Lilly and Company" with 2 trials as a collaborator, "Boston VA Research Institute, Inc." with 1 trials as a collaborator, "Brigham and Women's Hospital" with 1 trials as a collaborator, "Duke Clinical Research Institute" with 1 trials as a collaborator and "National Heart, Lung, and Blood Institute (NHLBI)" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Carient Heart and Vascular" are "Heart Failure" (3 trials), "Myocardial Infarction" (2 trials), "ASCVD" (1 trials), "Atherosclerotic Cardiovascular Disease" (1 trials) and "Atrial Fibrillation" (1 trials). Many other conditions were trialed in "Carient Heart and Vascular" in a lesser frequency.

Most popular intervention types in "Carient Heart and Vascular" are "Drug" (4 trials), "Device" (2 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Empagliflozin" (2 trials), "Apixaban" (1 trials), "Apixaban matching placebo" (1 trials) and "Asundexian (BAY2433334)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Carient Heart and Vascular" are 9 trials for "All" genders.

Currently, there are NaN active trials in "Carient Heart and Vascular". undefined are not yet recruiting, 3 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Carient Heart and Vascular, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Carient Heart and Vascular, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".